Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240908 | 0.91 | TSHR (0.45) | TSHRPSMB5LMNANAPRTP4HTM | |
| SCHEMBL38661115 | 0.84 | TSHR (0.45) | TSHRPSMB5LMNAGAASMN1; SMN2 | |
| SCHEMBL240655 | 0.84 | SMN1; SMN2 (0.46) | TSHRLMNAL3MBTL1GAASMN1; SMN2 | |
| SCHEMBL27811093 | 0.81 | TSHR (0.41) | TSHRPSMB5LMNANAPRTP4HTM | |
| SCHEMBL1177985 | 0.81 | CYP19A1 (0.54) | TSHRPSMB5LMNAL3MBTL1GAA | |
| SCHEMBL7414860 | 0.80 | TSHR (0.40) | TSHRPSMB5LMNANAPRTP4HTM | |
| SCHEMBL4996914 | 0.80 | ALDH1A1 (0.45) | TSHRLMNAGAASMN1; SMN2NPC1 | |
| SCHEMBL30571184 | 0.80 | ALDH1A1 (0.45) | TSHRLMNAGAASMN1; SMN2NPC1 | |
| SCHEMBL6245082 | 0.80 | TSHR (0.40) | TSHRPSMB5LMNANAPRTP4HTM | |
| SCHEMBL14501436 | 0.80 | SMN1; SMN2 (0.44) | TSHRLMNANAPRTP4HTML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117440945-A | Pyrimidine or pyridine derivative, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-115867539-A | 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115836064-A | Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| EP-3109227-B1 | METHOD FOR CONTINUOUSLY PRODUCING KETOMALONIC ACID COMPOUND USING FLOW REACTOR | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-105980345-B | Method for continuously producing ketomalonic acid compound using flow reactor | 组合化学工业株式会社 | 2019-12-20 | — | — | CN | disclosed |
| WO-2019109150-A1 | METHODS OF TREATING AGITATION | BIONOMICS LIMITED (AU) | 2019-06-13 | — | — | WO | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| EP-3023411-B1 | PRODUCTION METHOD OF KETOMALONIC ACID COMPOUND | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180305290-A1 | METHOD FOR CONTINUOUSLY PRODUCING KETOMALONIC ACID COMPOUND USING FLOW REACTOR | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-1091953-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE & CO (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003040127-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. SEARLE LLC (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6387924-B2 | ATHEROSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTILIPIDEMIC AGENTS | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. | 2002-01-31 | — | — | US | disclosed |
| US-6262277-B1 | IN MEDICINE FOR PROPHYLAXIS AND THERAPY OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-1091953-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6107494-A | FOR TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000001687-A9 | BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE & CO (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000001687-A1 | BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE & CO. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | TSHR 4128/4885PSMB5 2236/4885LMNA 3300/4885 |
| US-20180305290-A1 | METHOD FOR CONTINUOUSLY PRODUCING KETOMALONIC ACID COMPOUND USING FLOW REACTOR | ME1, ME3, CA6 | TSHR 3838/4885PSMB5 2616/4885LMNA 4446/4885 |
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | TSHR 1298/4885PSMB5 1118/4885LMNA 2761/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | TSHR 1279/4885PSMB5 1142/4885LMNA 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.